homefeedbacksupportlog on 7-Oct-2008 
  About F1000

 What is F1000 Biology?
 Key features
 How it's organized
 FAQs
 Faculties and sections
 Scope of sections
 List of Faculty Members
 The evaluation system
 Citing F1000
 Take a tour of the site
 Accessing fulltexts
 PubMed linkout
 How to subscribe
 Academic subscriptions
 Corporate subscriptions
 Try F1000 for free
 Who we are
 Media information
 Librarian resources
 Press releases
 In the press
 Developing countries
 F1000 Medicine
 Terms and conditions
 Privacy policy
 Contact us


Susan Bates
Medicine Branch, National Cancer Institute, Bethesda, United States of America

Faculty Member: Pharmacology & Drug Discovery > Cancer Therapeutics [ since 14 February 2008 ]
[ Evaluations ]
to email [Help]
Evaluations

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
Larson RA, Druker BJ, …, Wang Y, IRIS (International Randomized Interferon vs STI571) Study Group
Blood 2008 Apr 15 111(8):4022-8 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Susan Bates
Evaluated 28 Aug 2008

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.
Picard S, Titier K, …, Molimard M, Mahon FX
Blood 2007 Apr 15 109(8):3496-9 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Susan Bates
Evaluated 28 Aug 2008


CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.
van den Heuvel-Eibrink MM, van der Holt B, …, Löwenberg B, Sonneveld P
Ann Hematol 2007 May 86(5):329-37 [abstract on PubMed] [related articles] [FREE full text]
Selected by | Susan Bates
Evaluated 14 May 2008

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Schroth W, Antoniadou L, …, Eichelbaum M, Brauch H
J Clin Oncol 2007 Nov 20 25(33):5187-93 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Susan Bates
Evaluated 13 May 2008

Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 BCRP) Gene Polymorphisms in Humans.
Yamasaki Y, Ieiri I, …, Higuchi S, Sugiyama Y
Clin Pharmacol Ther 2008 Jan 2 [abstract on PubMed] [related articles] [full text]
Selected by | Susan Bates
Evaluated 13 May 2008

The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells.
Xie Y, Xu K, …, Gleave ME, Qiu Y
J Biol Chem 2008 Feb 8 283(6):3349-56 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Susan Bates
Evaluated 18 Mar 2008

P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
de Vries NA, Zhao J, …, Beijnen JH, van Tellingen O
Clin Cancer Res 2007 Nov 1 13(21):6440-9 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Susan Bates
Evaluated 17 Mar 2008

^Top  Back to Faculty Members


© 1999-2008 Biology Reports Ltd unless otherwise stated < info@f1000.com >   Terms and conditions   Legal info